s-1743 has been researched along with ceritinib* in 1 studies
1 trial(s) available for s-1743 and ceritinib
| Article | Year |
|---|---|
Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated.. A healthy subject drug-drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg dose of ceritinib. To further investigate the impact of PPIs on the PK and efficacy of ceritinib in ALK-positive cancer patients, two subgroup analyses were performed. Analysis 1 evaluated ceritinib steady-state trough concentration (C. In the healthy subject study, co-administration of a single 750 mg dose of ceritinib with esomeprazole 40 mg for 6 days decreased ceritinib AUC. Long-term administration of ceritinib with PPIs does not adversely affect the PK and efficacy of ceritinib in ALK-positive cancer patients. Topics: Adolescent; Adult; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Esomeprazole; Female; Healthy Volunteers; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones; Treatment Outcome; Young Adult | 2017 |